Keywords: merck, serono, expands, cilengitide, program, division, germany

Merck Serono expands cilengitide program

Article | 23 March 2009

Print This

Merck Serono, a division of Germany's Merck KGaA, has initiated a Phase II CERTO study, which will investigate the efficacy ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in